Loss of function germline mutations in RAD51D in women with ovarian carcinoma

被引:35
|
作者
Wickramanyake, Anneka
Bernier, Greta [2 ,3 ]
Pennil, Christopher
Casadei, Silvia [2 ]
Agnew, Kathy J.
Stray, Sunday M. [2 ]
Mandell, Jessica [2 ]
Garcia, Rochelle L. [4 ]
Walsh, Tom [2 ]
King, Mary-Claire [2 ]
Swisher, Elizabeth M. [1 ,2 ]
机构
[1] Univ Washington, Med Ctr, Dept Obstet & Gynecol, Div Gynecol Oncol,Sch Med, Seattle, WA 98195 USA
[2] Univ Washington, Sch Med, Dept Med, Div Med Genet, Seattle, WA 98195 USA
[3] Univ Washington, Sch Med, Dept Surg, Seattle, WA 98195 USA
[4] Univ Washington, Sch Med, Dept Pathol, Seattle, WA 98195 USA
关键词
RAD51D; Ovarian cancer; Breast cancer; CANCER; BREAST;
D O I
10.1016/j.ygyno.2012.09.009
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Objective. RAD51D, a gene in the Fanconi Anemia-BRCA homologous recombination pathway, has recently been shown to harbor germline mutations responsible for ovarian carcinoma in multiply affected families. We aimed to extend these results to ovarian carcinoma in the general population. Methods. We sequenced RAD51D in germline DNA from 360 individuals with primary ovarian, peritoneal or fallopian tube carcinoma who were not selected for age of cancer onset or family history. We also sequenced RAD51D in 459 probands from 226 high risk breast cancer families who were wild type for 21 breast and ovarian cancer genes. Results. Of 360 cases, three (0.8%) carried loss-of-function mutations in RAD51D. All three subjects had ovarian carcinoma; one was also diagnosed with a synchronous endometrial carcinoma. Only one of the three subjects had a family history of breast or ovarian cancer. Combined with previous data for this series, 23.9% of women with unselected ovarian, fallopian tube, or peritoneal carcinoma carried a germline loss-of-function mutation in any of 13 tumor suppressor genes. Among the 449 women and 10 men with familial breast cancer, none carried a loss of function mutation in RAD51D. Conclusions. These data support the previous observation that loss-of-function mutations in RAD51D predispose to ovarian carcinoma but not to breast carcinoma. We conclude that inherited ovarian cancer is highly heterogeneous genetically, and that approximately one in four ovarian carcinoma patients carry a germline mutation in a known tumor suppressor gene that confers high risk. (C) 2012 Elsevier Inc. All rights reserved.
引用
收藏
页码:552 / 555
页数:4
相关论文
共 50 条
  • [1] Germline mutations in RAD51D confer susceptibility to ovarian cancer
    Loveday, Chey
    Turnbull, Clare
    Ramsay, Emma
    Hughes, Deborah
    Ruark, Elise
    Frankum, Jessica R.
    Bowden, Georgina
    Kalmyrzaev, Bolot
    Warren-Perry, Margaret
    Snape, Katie
    Adlard, Julian W.
    Barwell, Julian
    Berg, Jonathan
    Brady, Angela F.
    Brewer, Carole
    Brice, Glen
    Chapman, Cyril
    Cook, Jackie
    Davidson, Rosemarie
    Donaldson, Alan
    Douglas, Fiona
    Greenhalgh, Lynn
    Henderson, Alex
    Izatt, Louise
    Kumar, Ajith
    Lalloo, Fiona
    Miedzybrodzka, Zosia
    Morrison, Patrick J.
    Paterson, Joan
    Porteous, Mary
    Rogers, Mark T.
    Shanley, Susan
    Walker, Lisa
    Eccles, Diana
    Evans, D. Gareth
    Renwick, Anthony
    Seal, Sheila
    Lord, Christopher J.
    Ashworth, Alan
    Reis-Filho, Jorge S.
    Antoniou, Antonis C.
    Rahman, Nazneen
    NATURE GENETICS, 2011, 43 (09) : 879 - U90
  • [2] Contribution of Germline Mutations in the RAD51B, RAD51C, and RAD51D Genes to Ovarian Cancer in the Population
    Song, Honglin
    Dicks, Ed
    Ramus, Susan J.
    Tyrer, Jonathan P.
    Intermaggio, Maria P.
    Hayward, Jane
    Edlund, Christopher K.
    Conti, David
    Harrington, Patricia
    Fraser, Lindsay
    Philpott, Susan
    Anderson, Christopher
    Rosenthal, Adam
    Gentry-Maharaj, Aleksandra
    Bowtell, David D.
    Alsop, Kathryn
    Cicek, Mine S.
    Cunningham, Julie M.
    Fridley, Brooke L.
    Alsop, Jennifer
    Jimenez-Linan, Mercedes
    Hogdall, Estrid
    Hogdall, Claus K.
    Jensen, Allan
    Kjaer, Susanne Krueger
    Lubinski, Jan
    Huzarski, Tomasz
    Jakubowska, Anna
    Gronwald, Jacek
    Poblete, Samantha
    Lele, Shashi
    Sucheston-Campbell, Lara
    Moysich, Kirsten B.
    Odunsi, Kunle
    Goode, Ellen L.
    Menon, Usha
    Jacobs, Ian J.
    Gayther, Simon A.
    Pharoah, Paul D. P.
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (26) : 2901 - +
  • [3] A decade of RAD51C and RAD51D germline variants in cancer
    Boni, Jacopo
    Idani, Aida
    Roca, Carla
    Feliubadalo, Lidia
    Tomiak, Eva
    Weber, Evan
    Foulkes, William D.
    Orthwein, Alexandre
    El Haffaf, Zaki
    Lazaro, Conxi
    Rivera, Barbara
    HUMAN MUTATION, 2022, 43 (03) : 285 - 298
  • [4] Clinical characteristics and survival analysis of Chinese ovarian cancer patients with RAD51D germline mutations
    Yao, Hongwen
    Li, Ning
    Yuan, Hua
    BMC CANCER, 2022, 22 (01)
  • [5] Secondary Somatic Mutations Restoring RAD51C and RAD51D Associated with Acquired Resistance to the PARP Inhibitor Rucaparib in High-Grade Ovarian Carcinoma
    Kondrashova, Olga
    Nguyen, Minh
    Shield-Artin, Kristy
    Tinker, Anna V.
    Teng, Nelson N. H.
    Harrell, Maria I.
    Kuiper, Michael J.
    Ho, Gwo-Yaw
    Barker, Holly
    Jasin, Maria
    Prakash, Rohit
    Kass, Elizabeth M.
    Sullivan, Meghan R.
    Brunette, Gregory J.
    Bernstein, Kara A.
    Coleman, Robert L.
    Floquet, Anne
    Friedlander, Michael
    Kichenadasse, Ganessan
    O'Malley, David M.
    Oza, Amit
    Sun, James
    Robillard, Liliane
    Maloney, Lara
    Bowtell, David
    Giordano, Heidi
    Wakefield, Matthew J.
    Kaufmann, Scott H.
    Simmons, Andrew D.
    Harding, Thomas C.
    Raponi, Mitch
    McNeish, Iain A.
    Swisher, Elizabeth M.
    Lin, Kevin K.
    Scott, Clare L.
    CANCER DISCOVERY, 2017, 7 (09) : 984 - 998
  • [6] RAD51C germline mutations in breast and ovarian cancer patients
    Mohammad R Akbari
    Patricia Tonin
    William D Foulkes
    Parviz Ghadirian
    Marc Tischkowitz
    Steven A Narod
    Breast Cancer Research, 12
  • [7] Germline RAD51C mutations in ovarian cancer susceptibility
    Coulet, F.
    Fajac, A.
    Colas, C.
    Eyries, M.
    Dion-Miniere, A.
    Rouzier, R.
    Uzan, S.
    Lefranc, J-P
    Carbonnel, M.
    Cornelis, F.
    Cortez, A.
    Soubrier, F.
    CLINICAL GENETICS, 2013, 83 (04) : 332 - 336
  • [8] Germline RAD51C mutations confer susceptibility to ovarian cancer
    Loveday, Chey
    Turnbull, Clare
    Ruark, Elise
    Xicola, Rosa Maria Munoz
    Ramsay, Emma
    Hughes, Deborah
    Warren-Perry, Margaret
    Snape, Katie
    Eccles, Diana
    Evans, D. Gareth
    Gore, Martin
    Renwick, Anthony
    Seal, Sheila
    Antoniou, Antonis C.
    Rahman, Nazneen
    NATURE GENETICS, 2012, 44 (05) : 475 - 476
  • [9] Germline genetic variants in a case of familial cancer: RAD51D and four other co-segregated variants
    Biswas, Shristi
    Manekar, Swati
    Kantharia, Shehnaz
    Bakshi, Sonal
    JOURNAL OF GENETICS, 2024, 103 (02)
  • [10] Association between polymorphisms in MicroRNA target sites of RAD51D genes and risk of hepatocellular carcinoma
    Jiang, Yan-Ji
    Zhong, Jian-Hong
    Zhou, Zi-Han
    Qiu, Mo-Qin
    Zhou, Xian-Guo
    Liu, Ying-Chun
    Huo, Rong-Rui
    Liang, Xiu-Mei
    Chen, Zhu
    Lin, Qiu-Ling
    Yu, Xiang-Yuan
    Yu, Hong-Ping
    CANCER MEDICINE, 2019, 8 (05): : 2545 - 2552